Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4391-4400 Newer>

The Motley Fool November 30, 2007 Brian Lawler	MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S.
The Motley Fool November 30, 2007 Brian Orelli	Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way.
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
The Motley Fool November 30, 2007 Brian Lawler	FDA Throws Adolor a Bone Pharmaceutical company Adolor gets an advisory panel hearing on its lead drug. Investors, take note.
The Motley Fool November 30, 2007 Brian Lawler	Not What Trimeris Needs Small biopharma Trimeris revealed that it and partner Roche were being sued for patent infringement by Novartis over Trimeris' only marketed compound, Fuzeon.
The Motley Fool November 30, 2007 Brian Orelli	Increased Potency Increases Stock Price Sirtris Pharmaceuticals publishes an article this week in Nature that characterized its discovery of drugs that are 1000 times more potent than resveratrol, the compound found in red wine that makes mice live longer and lowers blood sugar levels in obese mice.
Popular Mechanics November 29, 2007	Efficient, Cancer-Free Scanner Could Mean Ixnay on the X-Ray While X-rays do a pretty good job, a new portable scanner for medical imaging and security screening suggests we may soon have a better option: T-rays.
The Motley Fool November 29, 2007 Brian Lawler	Another Chapter in Glaxo's Relenza Saga An FDA advisory panel suggested that the Relenza label should be strengthened to include the possibility of abnormal behavior and hallucinations in those who take it.
The Motley Fool November 29, 2007 Brian Lawler	QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale.
Popular Mechanics November 28, 2007	Dental Tech Coming Soon to a Mouth Near You You'll be happy these oral solutions are right around the corner -- digital dental imagery and reduced-risk root canal.
<Older 4391-4400 Newer> Return to current articles.